Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

MDXGBullishM&Anews

High materiality9/10

MiMedx to Acquire Sanara MedTech, Expanding Surgical Footprint and Profitability

Jul 29, 2026, 4:04 PM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The deal provides immediate accretion potential, significant revenue and margin expansion, and a clear near-term catalyst (closing by year-end). Financing structure and premium to SMTI support a positive price reaction for MDXG, though dilution and leverage post-close warrant monitoring.

AI summary

What happened, with direct paths to the underlying reporting

MiMedx Group (MDXG) announced a definitive merger with Sanara MedTech (SMTI) valued at about $350 million. The combination would nearly double MDXG’s surgical revenue and targets over $400 million in 2027 revenue with EBITDA margins above 20%, supported by over $20 million in run-rate cost synergies. Closing is expected by year-end 2026, subject to regulatory approvals and SMTI shareholder voting, with a conference call today.

MiMedx Group to acquire Sanara MedTech in a cash-and-stock deal valued at about $350m EV.
Sanara shareholders receive $33 cash and 0.4735 MDXG shares per SMTI share, valuing SMTI at $35/share.
Deal nearly doubles MDXG’s surgical revenue; 2027 revenue expected well over $400m with >20% Adj EBITDA.
Financing includes a $300m term loan from Hayfin; closing targeted by year-end 2026.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.